Avizakimab, formerly known as BOS161721, represents a promising therapeutic approach to treating immune-mediated diseases . This antibody medication selectively targets interleukin-18 , a crucial protein https://ammariefq587827.aboutyoublog.com/52869914/avizakimab-a-thorough-analysis-into-bos161721-s-capability